glp 1 drugs and blindness Risk Comparing Ozempic, Wegovy and Other

So how do these benefits occur

Diabetes care 27 (8), 18791884

Medication-cycle tools can be useful when the main job is understanding how a dose may rise, peak, or fade

Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications can identify a subgroup of patients with T2D at high risk of mortality who are likely to achieve the greatest benefit from newer glucose-lowering agents

However, CagriSema and retatrutide (both in late-stage development) more closely match tirzepatide weight loss results , with CagriSema achieving 20% and retatrutide achieving up to 29% body weight reduction in trials

Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction